GlaxoSmithKline unveil revised executive wages

Pharmaceuticals giant GlaxoSmithKline today bowed to shareholder pressure and unveiled revised pay and rewards contracts for executives.

Pharmaceuticals giant GlaxoSmithKline today bowed to shareholder pressure and unveiled revised pay and rewards contracts for executives.

It scrapped the two-year rolling contracts for executive directors that had sparked investor anger earlier this year over “fat cat” pay, replacing them with a single year deal without compensation.

You have reached your article limit. Already a subscriber? Sign in

Clubber TV and Irish Examiner logos in offer banner

Every Match. Every Story.

One Ultimate Bundle

No obligation. Ts&Cs apply.

More in this section

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited